A Live Meeting Series for PCPs
Shining a Light on the PCP’s Role in HIV Prevention
Suggested Readings
Antiretroviral prophylaxis for HIV prevention in heterosexual men and women.
Baeten JM, et al. N Engl J Med. 2012;367(5):399-410.
Antiretroviral prophylaxis for HIV infection in injecting drug users in Bangkok, Thailand (the Bangkok Tenofovir Study): a randomised, double-blind, placebo-controlled phase 3 trial.
Choopanya K, et al. Lancet. 2013;381(9883):2083-2090.
Emtricitabine/tenofovir alafenamide.
HIV.gov. Drug database.
Emtricitabine/tenofovir disoproxil fumarate.
HIV.gov. Drug database.
Cabotegravir.
HIV.gov. Drug database.
Lenacapavir.
HIV.gov. Drug database.
Being PrEPared—preexposure prophylaxis and HIV disparities.
Goldstein RH, et al. N Engl J Med. 2018;379(14):1293-1295.
Preexposure chemoprophylaxis for HIV prevention in men who have sex with men.
Grant RM, et al. N Engl J Med. 2010;363(27):2587-2599.
Lifetime risk of a diagnosis of HIV infection in the United States.
Hess KL, et al. Ann Epidemiol. 2017;27(4):238-243.
Cabotegravir for HIV prevention in cisgender men and transgender women.
Landovitz RJ, et al. N Engl J Med. 2021;385(7):595-608.
Cabotegravir for the prevention of HIV-1 in women: results from HPTN 084, a phase 3, randomised clinical trial.
Delany-Moretlwe S, et al. Lancet. 2022;399(10337):1779-1789.
Emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV pre-exposure prophylaxis (DISCOVER): primary results from a randomised, double-blind, multicentre, active-controlled, phase 3, non-inferiority trial.
Mayer KH, et al. Lancet. 2020;396(10246):239-254.
Twice-yearly lenacapavir or daily F/TAF for HIV prevention in cisgender women.
Bekker, et al. N Engl J Med. 2024;391(13):1179-1192.
Twice-yearly lenacapavir for HIV prevention in men and gender-diverse persons.
N Engl J Med. 2025;392(13):1261-1276.
PrEP Access, Assistance, and Information
Patient and Provider assistance: PleasePrEPMe.org.
Information about PrEP, nPEP, insurance and insurance rights, finding a PrEP/nPEP provider, and a list of PrEP resources by state
Provider assistance: AETC; AIDS Education & Training Center Program: National Coordinating Resource Center
Supports national HIV priorities by providing training, consultation, and resources
Patient assistance (without insurance).
The PrEP patient assistance program will provide medication at no cost for those who meet income guidelines.
Uninsured 24/7 support online, by phone during business hours and fax enrollment:
Copay assistance (for patients with nongovernment insurance).
Phone number: 1-800-226-2056
Copay assistance/out-of-pocket costs.
ViiV Connect.
Linked Resources
